Goldman Sachs’s Trillium Therapeutics Inc. TRIL Stock Holding History

Goldman Sachs’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,263,721	Closed	-$22.2M	–	6912
2021 Q3	$22.2M	Buy	1,263,721 +762,279	+152%	+$8.91M	﹤0.01%	1972
2021 Q2	$4.86M	Buy	501,442 +398,567	+387%	+$3.75M	﹤0.01%	3367
2021 Q1	$1.1M	Sell	102,875 -142,467	-58%	-$1.76M	﹤0.01%	4529
2020 Q4	$3.61M	Buy	245,342 +67,781	+38%	+$977K	﹤0.01%	3263
2020 Q3	$2.52M	Sell	177,561 -24,272	-12%	-$242K	﹤0.01%	3407
2020 Q2	$1.63M	Buy	201,833 +89,182	+79%	+$552K	﹤0.01%	3595
2020 Q1	$455K	Buy	+112,651	New	+$426K	﹤0.01%	4274

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Goldman Sachs's TRIL Position: Q4 2021 in Review

Goldman Sachs sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,263,721 shares — an estimated $22.2M sold.

Goldman Sachs first reported a position in TRIL in Q1 2020 and held it in 7 quarters. The position peaked at $22.2M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Goldman Sachs reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Goldman Sachs sold 1,263,721 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $22.2M.
Goldman Sachs first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 7 quarters.
Goldman Sachs's Trillium Therapeutics Inc. position peaked at $22.2M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.